Cytek Biosciences, Inc.
Price Action
Technical Summary
CONSOLIDATINGCytek Biosciences, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 51), indicating performance broadly in line with the market. Earnings contraction of 67% provides fundamental context to the price action. Investors should exercise caution due to high volatility (59% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.12 | +5.38% | ABOVE |
| 50 SMA | $4.20 | +3.44% | ABOVE |
| 100 SMA | $4.31 | +0.77% | ABOVE |
| 150 SMA | $4.62 | -5.96% | BELOW |
| 200 SMA | $4.49 | -3.31% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CTKB in an uptrend right now?
CTKB has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is CTKB overbought or oversold?
CTKB's RSI (14) is 61. The stock is in neutral territory, neither overbought nor oversold.
Is CTKB outperforming the market?
CTKB has a Relative Strength (RS) Rating of 51 out of 99. CTKB is performing about average compared to the market.
Where is CTKB in its 52-week range?
CTKB is trading at $4.34, which is 70% of its 52-week high ($6.18) and 40% above its 52-week low ($3.09).
How volatile is CTKB?
CTKB has a Beta of 1.23 and 52-week volatility of 59%. It's more volatile than the S&P 500 - expect bigger swings.